Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06414837 Not yet recruiting - Clinical trials for Gout With Hyperuricemia in Adults

Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

NCT ID: NCT06207045 Not yet recruiting - Gout Flare Clinical Trials

The Effects of Limb Elevation During Gout Flare Episodes

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this open-label randomized controlled trial is to explore the benefit of limb elevation in inpatient gout flare episodes, compared with standard treatment The main questions are; - Is limb elevation able to reduce pain during gout flare episodes to a greater degree compared with standard treatment ? - Is Is limb elevation able to reduce joint swelling during gout flare episodes to a greater degree compared with standard treatment ? Participants will be divided into 2 group; 1. Limb elevation group 2. control group All participants will receive standard medical therapy consisting of colchicine 0.6 mg per day plus prednisolone 30 mg per day for 2 days Pain score and joint circumference will be recored at recruitment, 24 hour and 48 hour

NCT ID: NCT06187519 Not yet recruiting - Gout Clinical Trials

UR+AIMS Gout Wearable Skin Uric Acid Monitor Study

Start date: September 30, 2024
Phase: N/A
Study type: Interventional

15 patients with gout [10 patients no recent urate-lowering therapy (ULT) and 5 patients on stable urate-lowering therapy (ULT)] will be invited to participate in a standardized meal at the UCLA Human Nutrition Center and a 7-day community follow-up for the measurement of uric acid (and other metabolites) using our Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch.

NCT ID: NCT06169891 Not yet recruiting - Acute Gout Clinical Trials

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Start date: December 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of recombinant anti-IL-1β humanized monoclonal antibody injection in Chinese participants with acute gout.

NCT ID: NCT06139393 Not yet recruiting - Clinical trials for Gout With Hyperuricemia in Adults

Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Start date: November 2023
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

NCT ID: NCT05936281 Not yet recruiting - Acute Gout Clinical Trials

Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy

Gensci 048-202
Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Genakumab for Injection in patients with gout initiating urico-lowering therapy

NCT ID: NCT05925166 Not yet recruiting - Acute Gout Clinical Trials

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the efficacy and safety of Recombinant Human Tumor necrosis Factor-α Receptor Ⅱ Fusion Protein (rhTNFR-Fc)in the treatment of patients with acute Gout.

NCT ID: NCT05800041 Not yet recruiting - Gout Tophus Clinical Trials

A Exploratory Trial of WTX221 in Refractory Gout Patients

Start date: April 10, 2023
Phase: Early Phase 1
Study type: Interventional

This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to investigate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of multiple doses of WTX221 infusion combined with a single dose of the immunosuppressive agent cyclophosphamide (CTX) to induce immune tolerance. The trial consisted of a Screening Period (14 days), a First Dose Period (30 days), a Second Dose Period (30 days), and a Safety Follow-up Period (150 days) for a total of 224 days.

NCT ID: NCT05513976 Not yet recruiting - Clinical trials for Primary Gout and Hyperuricemia

Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Start date: September 15, 2022
Phase: Phase 2
Study type: Interventional

SHR4640 tablets is a highly selective and potent URAT1 inhibitors,study number is SHR4640-203. The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and febuxostat compared with placebo and febuxostat in primary gout and hyperuricemia subjects with inadequate control on febuxostat for 12 weeks.

NCT ID: NCT05507723 Not yet recruiting - Gout Clinical Trials

Tight Control of Gouty Arthritis Compared to Usual Care

TICOGA
Start date: October 2024
Phase: N/A
Study type: Interventional

Gout is caused by a reaction to urate crystals that results in attacks of severe joint pain. Medicines that lower urate levels can prevent gout flares, however it takes time for this benefit to be felt, and paradoxically starting treatment with large doses of urate lowering treatment risks provoking attacks of gout. Medical guidelines disagree on the best way to overcome these challenges with many recommending medicine dose adjustment based on regular urate testing but a general practice guideline suggesting more simply increasing the medicine dose in those patients that continue to suffer flares. In reality most patients are not treated at all, and many of those that are treated never receive an effective dose of treatment. We have developed a supported self-management approach to gout in which patients monitor their own urate levels using a finger prick test, and then receive advice on adjusting their treatment dose to achieve target urate levels through a smartphone app (Gout SMART). A trial of this approach has shown that it results in much better control of urate levels after 6 months than usual care, and suggests that it also leads to fewer flares. We would now like to confirm that this approach is effective in reducing flares of gout over 2 years by randomising patients to either treatment-to-target urate using our self-monitoring approach, or to treatment guided by symptoms only.